CA-NEXON-AMERICA
18.3.2022 14:02:11 CET | Business Wire | Press release
This week, MapleStory M , Nexon’s free-to-play mobile MMORPG, added the Cannoneer, an explosive and deadly new class accompanied by a playful monkey that provides attack support. A number of celebratory growth events mark the arrival of the Cannoneer, alongside a new season of the Daisy Style Festival, where mobile Maplers have the chance to earn rewards by impressing their fellow players with their fashion sense.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220318005071/en/
The Cannoneer uses its titular weapon, a deadly hand cannon forged by the Nautilus’ resident inventor, to deal massive damage with a wide attack range. This powerful pirate is accompanied by his best friend, a monkey befriended on Coco Island, who provides attack support in combat. In addition to dealing damage, the Cannoneer can use his Pirate Blessing skill to buff other characters in the same party.
This class joins MapleStory M with three celebratory events to support the growth of new Cannoneers and their adorable primate companions:
- Cannoneer On-Time Event - Login from March 16 to March 23 to receive rewards including character slot coupons, auto-battle tickets, pet packages, and more!
- Cannoneer Mega Burning Event - From March 16 to April 19, Maplers can select one character as a Mega Burning Character that will then receive 2 additional levels each time they level up.
- Cannoneer Growth Support Mission - From March 16 to April 19, Cannoneer characters can attempt various missions to receive various rewards that will support their growth. On top of growth-focused rewards, completing certain missions will also grant Cannoneer exclusive cosmetics.
This update also marks the start of Season 2 of the Daisy Style Festival , which runs until March 30. This fashion competition invites Maplers to register their characters in order to show off their sense of style and vote for the best styles from other players. Rewards including event coins, titles, and more will be awarded based on the number of votes received from fellow Maplers. Players can vote twice per day and register their style once per week, per account.
To learn more about MapleStory M, visit the App Store or Google Play Store page and follow @PlayMapleM on Twitter for the latest updates.
Assets: Artwork
Social Media: Facebook / Instagram / Twitter / Twitch / YouTube / Discord
About MapleStory M
https://maplestorym.nexon.com/
MapleStory M
, launched globally on July 24, 2018, brings the nostalgic world of side-scrolling MMORPG MapleStory
to mobile, offering the same endless amount of customization, immersive storylines and epic boss raids that fans have come to expect from the legendary franchise. MapleStory M
quickly reached 10 million downloads within 100 days after global launch and last year celebrated its 3-year anniversary with 16 million global downloads.
About Nexon America Inc.
https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory
and Mabinogi
for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220318005071/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom